New radiation combo aims to shrink sarcomas before surgery

NCT ID NCT07501026

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether a special type of radiation therapy (SFRT) given before surgery can improve outcomes for people with large soft tissue sarcomas (at least 5 cm) in the limbs or trunk. About 22 adults will receive 5 doses of SFRT, then have surgery about a week later. Researchers will track how many patients are cancer-free after one year, how well the tumor responds, and any side effects. Blood samples will also be taken to study how the immune system reacts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: spatially fractionated radiation therapy (SFRT)
What this could lead to: If successful, this approach could improve disease-free survival and tumor response before surgery for large soft tissue sarcomas, potentially offering a new standard preoperative option.
What could go wrong: This is a small, early-phase (phase II) trial with only 22 participants, so results may not apply broadly. Radiation side effects and surgical complications are possible, and the benefit over current treatments is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

2nd Affiliated Hospital, School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.